3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
7
Phase 2
4
Phase 1/2
4
Phase 4
1
Phase 3
1
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Cytokine Release Syndrome
1
Interventions
Specimen Handling
3
Cisplatin
3
Magnetic Resonance Spectroscopy
2
Letrozole
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Diosmin
2
Carboplatin
2
trametinib
1
toripalimab
1
tocilizumab
1
sofosbuvir-velpatasvir drug combination
1
ruxolitinib
1
rozanolixizumab
1
pyrotinib
1
pirtobrutinib
1
olutasidenib
1
obinutuzumab
1
niraparib
1
naldemedine
1
idelalisib
1
human papillomavirus vaccine, L1 type 16, 18
1
fluciclovine F-18
1
enfortumab vedotin
1
darolutamide
1
dabrafenib
1
cabozantinib
1
apalutamide
1
adacel
1
acalabrutinib
1
Watchful Waiting
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
tocilizumab
×
30 days
×
Clear all
NCT07609940
2026-05-27
POPLIN
Regeneron Pharmaceuticals
Phase 4
Not yet recruiting
30 enrolled